{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:25:15Z","timestamp":1715991915664},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,6,7]],"date-time":"2014-06-07T00:00:00Z","timestamp":1402099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,6,7]],"date-time":"2014-06-07T00:00:00Z","timestamp":1402099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s00105-013-2733-8","type":"journal-article","created":{"date-parts":[[2014,6,5]],"date-time":"2014-06-05T10:09:20Z","timestamp":1401962960000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Kutane Nebenwirkungen der medikament\u00f6sen Tumortherapie mit BRAF- und MEK-Inhibitoren"],"prefix":"10.1007","volume":"65","author":[{"given":"R.","family":"Gutzmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.C.","family":"K\u00e4hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Loquai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"M\u00f6ssner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00fcr Komitee \u201eKutane Nebenwirkungen\u201c","family":"der das ADO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,7]]},"reference":[{"key":"2733_CR1","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/S1470-2045(12)70413-8","volume":"14","author":"Anforth","year":"2013","unstructured":"Anforth R, Fernandez-Penas P, Long GV (2013) Cutaneous toxicities of RAF inhibitors. Lancet Oncol 14:e11\u2013e18","journal-title":"Lancet Oncol"},{"key":"2733_CR2","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","volume":"167","author":"Anforth","year":"2012","unstructured":"Anforth RM, Blumetti TC, Kefford RF et al (2012) Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 167:1153\u20131160","journal-title":"Br J Dermatol"},{"key":"2733_CR3","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1200\/JCO.2012.44.7755","volume":"31","author":"Anker","year":"2013","unstructured":"Anker CJ, Ribas A, Grossmann AH et al (2013) Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 31:e283\u2013e287","journal-title":"J Clin Oncol"},{"key":"2733_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","volume":"14","author":"Ascierto","year":"2013","unstructured":"Ascierto PA, Schadendorf D, Berking C et al (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14:249\u2013256","journal-title":"Lancet Oncol"},{"key":"2733_CR5","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1007\/s10637-010-9567-3","volume":"29","author":"Balagula","year":"2011","unstructured":"Balagula Y, Barth HK, Busam KJ et al (2011) Dermatologic side effects associated with the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 29:1114\u20131121","journal-title":"Invest New Drugs"},{"key":"2733_CR6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jamadermatol.2013.4200","volume":"149","author":"Boussemart","year":"2013","unstructured":"Boussemart L, Boivin C, Claveau J et al (2013) Vemurafenib and radiosensitization. JAMA Dermatol 149:855\u2013857","journal-title":"JAMA Dermatol"},{"key":"2733_CR7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","volume":"24","author":"Boussemart","year":"2013","unstructured":"Boussemart L, Routier E, Mateus C et al (2013) Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 24(6):1691\u20131697","journal-title":"Ann Oncol"},{"key":"2733_CR8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/ijd.12205","volume":"53","author":"Curry","year":"2014","unstructured":"Curry JL, Torres-Cabala CA, Kim KB et al (2014) Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol 53:376\u2013384","journal-title":"Int J Dermatol"},{"key":"2733_CR9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/bjd.12093","volume":"168","author":"Dalle","year":"2013","unstructured":"Dalle S, Poulalhon N, Debarbieux S, Thomas L (2013) Second primary melanomas on treatment with vemurafenib. Br J Dermatol 168:887\u2013888","journal-title":"Br J Dermatol"},{"key":"2733_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00105-010-2042-4","volume":"62","author":"Degen","year":"2011","unstructured":"Degen A, Alter M, Schenck F et al (2011) Cutaneous side effects of medical tumor therapy. Hautarzt 62(6):444\u2013450","journal-title":"Hautarzt"},{"key":"2733_CR11","first-page":"652","volume":"8","author":"Degen","year":"2010","unstructured":"Degen A, Alter M, Schenck F et al (2010) The hand-foot-syndrome associated with medical tumor therapy \u2013 classification and management. J Dtsch Dermatol Ges 8:652\u2013661","journal-title":"J Dtsch Dermatol Ges"},{"key":"2733_CR12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1684\/ejd.2012.1915","volume":"23","author":"Degen","year":"2013","unstructured":"Degen A, Volker B, Kapp A, Gutzmer R (2013) Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma. Eur J Dermatol 23:118","journal-title":"Eur J Dermatol"},{"key":"2733_CR13","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1056\/NEJMc1113752","volume":"366","author":"Dummer","year":"2012","unstructured":"Dummer R, Rinderknecht J, Goldinger SM (2012) Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 366:480\u2013481","journal-title":"N Engl J Med"},{"key":"2733_CR14","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694\u20131703","journal-title":"N Engl J Med"},{"key":"2733_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107\u2013114","journal-title":"N Engl J Med"},{"key":"2733_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/exd.12249","volume":"22","author":"Ganzenmueller","year":"2013","unstructured":"Ganzenmueller T, Hage E, Yakushko Y et al (2013) No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients. Exp Dermatol 22:725\u2013729","journal-title":"Exp Dermatol"},{"key":"2733_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/exd.12119","volume":"22","author":"Gelot","year":"2013","unstructured":"Gelot P, Dutartre H, Khammari A et al (2013) Vemurafenib: an unusual UVA-induced photosensitivity. Exp Dermatol 22:297\u2013298","journal-title":"Exp Dermatol"},{"key":"2733_CR18","first-page":"195","volume":"9","author":"Gutzmer","year":"2011","unstructured":"Gutzmer R, Becker JC, Enk A et al (2011) Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dtsch Dermatol Ges 9:195\u2013203","journal-title":"J Dtsch Dermatol Ges"},{"key":"2733_CR19","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1001\/archdermatol.2012.2649","volume":"148","author":"Haenssle","year":"2012","unstructured":"Haenssle HA, Kraus SL, Brehmer F et al (2012) Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch Dermatol 148:1183\u20131185","journal-title":"Arch Dermatol"},{"key":"2733_CR20","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1200\/JCO.2013.49.3528","volume":"32","author":"Harding","year":"2014","unstructured":"Harding JJ, Barker CA, Carvajal RD et al (2014) Cutis verticis tyrata in association with vemurafenib and whole-brain radiotherapy. J Clin Oncol 32:e54\u201356","journal-title":"J Clin Oncol"},{"key":"2733_CR21","first-page":"559","volume":"10","author":"Homey","year":"2012","unstructured":"Homey B, Gerber PA, Wollenberg A et al (2012) Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers. J Dtsch Dermatol Ges 10:559\u2013563","journal-title":"J Dtsch Dermatol Ges"},{"key":"2733_CR22","doi-asserted-by":"publisher","first-page":"6683","DOI":"10.1158\/1078-0432.CCR-07-4389","volume":"14","author":"Isomura","year":"2008","unstructured":"Isomura M, Oya N, Tachiiri S et al (2008) IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin Cancer Res 14:6683\u20136689","journal-title":"Clin Cancer Res"},{"key":"2733_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","volume":"18","author":"Lacouture","year":"2013","unstructured":"Lacouture ME, Duvic M, Hauschild A et al (2013) Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 18:314\u2013322","journal-title":"Oncologist"},{"key":"2733_CR24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/CMR.0000000000000044","volume":"24","author":"Liebner","year":"2014","unstructured":"Liebner DA, Walston SA, Cavaliere R et al (2014) Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib. Melanoma Res 24:172\u2013176","journal-title":"Melanoma Res"},{"key":"2733_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"McArthur","year":"2014","unstructured":"McArthur GA, Chapman PB, Robert C et al (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323\u2013332","journal-title":"Lancet Oncol"},{"key":"2733_CR26","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/CMR.0b013e3283573437","volume":"22","author":"Minor","year":"2012","unstructured":"Minor DR, Rodvien R, Kashani-Sabet M (2012) Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib. Melanoma Res 22:410\u2013411","journal-title":"Melanoma Res"},{"key":"2733_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/CMR.0b013e3283570792","volume":"22","author":"Monfort","year":"2012","unstructured":"Monfort JB, Pages C, Schneider P et al (2012) Vemurafenib-induced neutrophilic panniculitis. Melanoma Res 22:399\u2013401","journal-title":"Melanoma Res"},{"key":"2733_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11060-013-1127-1","volume":"113","author":"Narayana","year":"2013","unstructured":"Narayana A, Mathew M, Tam M et al (2013) Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113:411\u2013416","journal-title":"J Neurooncol"},{"key":"2733_CR29","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","volume":"30","author":"Oberholzer","year":"2012","unstructured":"Oberholzer PA, Kee D, Dziunycz P et al (2012) RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30:316\u2013321","journal-title":"J Clin Oncol"},{"key":"2733_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/jamadermatol.2013.7919","volume":"150","author":"Park","year":"2014","unstructured":"Park JJ, Hawryluk EB, Tahan SR et al (2014) Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. JAMA Dermatol 150:307\u2013311","journal-title":"JAMA Dermatol"},{"key":"2733_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/cup.12273","volume":"41","author":"Pattanaprichakul","year":"2014","unstructured":"Pattanaprichakul P, Tetzlaff MT, Lapolla WJ et al (2014) Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. J Cutan Pathol 41:326\u2013328","journal-title":"J Cutan Pathol"},{"key":"2733_CR32","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1684\/ejd.2013.2193","volume":"23","author":"Peuvrel","year":"2013","unstructured":"Peuvrel L, Ruellan AL, Thillays F et al (2013) Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. Eur J Dermatol 23:879\u2013881","journal-title":"Eur J Dermatol"},{"key":"2733_CR33","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/bjd.12555","volume":"169","author":"Regnier-Rosencher","year":"2013","unstructured":"Regnier-Rosencher E, Lazareth H, Gressier L et al (2013) Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas. Br J Dermatol 169:934\u2013938","journal-title":"Br J Dermatol"},{"key":"2733_CR34","doi-asserted-by":"publisher","first-page":"e58721","DOI":"10.1371\/journal.pone.0058721","volume":"8","author":"Rinderknecht","year":"2013","unstructured":"Rinderknecht JD, Goldinger SM, Rozati S et al (2013) RASopathic skin eruptions during vemurafenib therapy. PLoS One 8:e58721","journal-title":"PLoS One"},{"key":"2733_CR35","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1470-2045(13)70237-7","volume":"14","author":"Robert","year":"2013","unstructured":"Robert C, Dummer R, Gutzmer R et al (2013) Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol 14:733\u2013740","journal-title":"Lancet Oncol"},{"key":"2733_CR36","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2013.50.8473","volume":"31","author":"Rompoti","year":"2013","unstructured":"Rompoti N, Schilling B, Livingstone E et al (2013) Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity. J Clin Oncol 31:3844\u20133845","journal-title":"J Clin Oncol"},{"key":"2733_CR37","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1200\/JCO.2012.44.4265","volume":"31","author":"Satzger","year":"2013","unstructured":"Satzger I, Degen A, Asper H et al (2013) Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol 31(13):e220\u2013e222","journal-title":"J Clin Oncol"},{"key":"2733_CR38","doi-asserted-by":"publisher","first-page":"e320","DOI":"10.1200\/JCO.2012.45.8307","volume":"31","author":"Sinha","year":"2013","unstructured":"Sinha R, Edmonds K, Newton-Bishop J et al (2013) Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib. J Clin Oncol 31:e320\u2013e321","journal-title":"J Clin Oncol"},{"key":"2733_CR39","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/bjd.12010","volume":"167","author":"Sinha","year":"2012","unstructured":"Sinha R, Edmonds K, Newton-Bishop JA et al (2012) Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 167:987\u2013994","journal-title":"Br J Dermatol"},{"key":"2733_CR40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1105358","volume":"366","author":"Su","year":"2012","unstructured":"Su F, Viros A, Milagre C et al (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207\u2013215","journal-title":"N Engl J Med"},{"key":"2733_CR41","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jamadermatol.2013.5278","volume":"149","author":"Wenk","year":"2013","unstructured":"Wenk KS, Pichard DC, Nasabzadeh T et al (2013) Vemurafenib-induced DRESS. JAMA Dermatol 149:1242\u20131243","journal-title":"JAMA Dermatol"},{"key":"2733_CR42","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","volume":"158","author":"Yang","year":"2008","unstructured":"Yang CH, Lin WC, Chuang CK et al (2008) Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 158:592\u2013596","journal-title":"Br J Dermatol"},{"key":"2733_CR43","doi-asserted-by":"crossref","unstructured":"Yorio JT, Mays SR, Ciurea AM et al (2014) Case of vemurafenib-induced Sweet\u2019s syndrome. J Dermatol [Epub ahead of print]","DOI":"10.1111\/1346-8138.12430"},{"key":"2733_CR44","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","volume":"30","author":"Zimmer","year":"2012","unstructured":"Zimmer L, Hillen U, Livingstone E et al (2012) Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 30:2375\u20132383","journal-title":"J Clin Oncol"},{"key":"2733_CR45","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","volume":"148","author":"Zimmer","year":"2012","unstructured":"Zimmer L, Livingstone E, Hillen U et al (2012) Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 148:357\u2013361","journal-title":"Arch Dermatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-013-2733-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-013-2733-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-013-2733-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-013-2733-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T14:05:21Z","timestamp":1659362721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-013-2733-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["2733"],"URL":"https:\/\/doi.org\/10.1007\/s00105-013-2733-8","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,7]]},"assertion":[{"value":"7 June 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"582"}}